CAJ | 학술논문

目的观察比较吉西他滨联合替吉奥与吉西他滨单药治疗晚期胰腺癌的有效性和安全性. 方法 65例经病理证实的晚期胰腺癌患者按照随机对照原则分成吉西他滨+替吉奥联合组 (32例) 和吉西他滨单药组 (33例), 比较两组的临床结局. 结果联合组有效率为40.6%, 单药组为18.2%, 差异有统计学意义 (P<0.05). 此外, 两组中位疾病进展期分别为4.2个月和3.5个月 (P>0.05), 中位生存时间为8.4个月和7.5个月 (P>0.05). 不良反应主要为骨髓抑制、胃肠道反应, 两组不良反应发生率比较差异无统计学意义. 结论吉西他滨联合替吉奥治疗晚期胰腺癌近期疗效较吉西他滨单药更优, 毒副反应无明显加重.
목적 관찰비교길서타빈연합체길오여길서타빈단약치료만기이선암적유효성화안전성. 방법 65례경병리증실적만기이선암환자안조수궤대조원칙분성길서타빈+체길오연합조 (32례) 화길서타빈단약조 (33례), 비교량조적림상결국. 결과 연합조유효솔위40.6%, 단약조위18.2%, 차이유통계학의의 (P<0.05). 차외, 량조중위질병진전기분별위4.2개월화3.5개월 (P>0.05), 중위생존시간위8.4개월화7.5개월 (P>0.05). 불량반응주요위골수억제、 위장도반응, 량조불량반응발생솔비교차이무통계학의의. 결론 길서타빈연합체길오치료만기이선암근기료효교길서타빈단약경우, 독부반응무명현가중.
Objective To observe the efficacy and safety of gemcitabine plus S-1 versus gemcitabine on patients with advanced pancreatic cancer. Methods Sixty-five patients with advanced pancreatic cancer confirmed by pathology were randomly divided into combined therapy group (n=32, gemcitabine plus S-1) and control group (n=33, gemcitabine). The clinical outcomes of the two groups were compared. Results The response rate was 40.6%in the combined therapy group, and 18.2%in the control group, and the difference between the two groups was significant (P<0.05). No statistical difference was found between two groups in the median time to progression, median survival time and incidence of adverse reactions (all P>0.05). Conclusions Gemcitabine plus S-1 regimen has better efficacy in the treatment of advanced pancreatic cancer than gemcitabine, without significantly increased toxicity.